{"id":"diosmin","rwe":[{"pmid":"41903244","year":"2026","title":"Assessment of the inaccuracy associated with the quantification of phenolic compounds using UHPLC-DAD and HPLC-MS/MS.","finding":"","journal":"Journal of chromatography. A","studyType":"Clinical Study"},{"pmid":"41876507","year":"2026","title":"Stage-specific nutritional blueprints of date fruit revealed by integrated LC-MS metabolomics and ICP-OES profiling.","finding":"","journal":"NPJ science of food","studyType":"Clinical Study"},{"pmid":"41862140","year":"2026","title":"Smart Lipid-Based Nanocarrier System for the Topical Delivery of Ocular Therapeutics Bio-Interfacing, Physicochemical Diversity, and Routing Barriers.","finding":"","journal":"European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences","studyType":"Clinical Study"},{"pmid":"41830372","year":"2026","title":"The Flavonoids Hesperidin and Diosmin: Adjuvant Therapy for Obesity.","finding":"","journal":"JPMA. The Journal of the Pakistan Medical Association","studyType":"Clinical Study"},{"pmid":"41767423","year":"2026","title":"Effectiveness of Conservative Treatment on Chronic Venous Disease Symptoms and Quality of Life in Patients with Type 2 Diabetes: Results from a Subanalysis of the VEIN STEP Observational Study.","finding":"","journal":"Vascular health and risk management","studyType":"Clinical Study"}],"_fda":{"id":"24245e80-529f-0542-e063-6394a90a1fb4","set_id":"24245e80-529f-0542-e063-6394a90a1fb4","openfda":{"unii":["OZ0E5Y15PZ","7QM776WJ5N","E750O06Y6O","4T2GVA922X","5G06TVY3R7","S033EH8359","ZLM4P8929R","ALO92O31SE"],"route":["ORAL"],"spl_id":["24245e80-529f-0542-e063-6394a90a1fb4"],"brand_name":["Bruselix Bruising"],"spl_set_id":["24245e80-529f-0542-e063-6394a90a1fb4"],"package_ndc":["59088-003-81"],"product_ndc":["59088-003"],"generic_name":["VITAMIN C, ZINC, ARNICA MONTANA EXTRACT, BROMELAIN, DIOSMIN, RUTIN, CITRUS BIOFLAVONOIDS, HESPERIDIN METHYL CHALCONE"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["ARNICA MONTANA FLOWER","DIOSMIN","HESPERIDIN","HESPERIDIN METHYLCHALCONE","RUTIN","SODIUM ASCORBATE","STEM BROMELAIN","ZINC PICOLINATE"],"manufacturer_name":["Puretek Corporation"],"is_original_packager":[true]},"version":"1","overdosage":["OVERDOSE: In the event of overdose, seek medical attention immediately. Symptoms of overdose may include gastrointestinal upset, nausea, or an increased risk of bleeding due to excess Bromelain."],"description":["DESCRIPTION: Active Ingredients Each tablet contains: Vitamin C (as Sodium Ascorbate) ...............................................................120 mg Zinc (as Zinc Picolinate) ...............................................................................10 mg Arnica Montana Extract 10:1 (equivalent to 500 mg Arnica Montana Powder) ...50 mg Bromelain 2400 GDU/g (from Pineapple) ...................................................400 mg Diosmin (Citrus Aurantium) Fruit Extract.....................................................200 mg Rutin (Sophora Japonica) Flower Extract......................................................50 mg Citrus Bioflavonoids (from pulp and peel of lemon, orange, quince) ............25 mg Hesperidin Methyl Chalcone..........................................................................25 mg Other Ingredients: Croscarmellose Sodium, Dicalcium Phosphate, Magnesium Stearate, Microcrystalline Cellulose, Silicon Dioxide, Stearic Acid (Vegetable Source), Coating (Hydroxypropyl Methylcellulose, PEG-8)."],"how_supplied":["HOW SUPPLIED: Bruselix™ Bruising Tablets are yellow to brown speckled, clear-coated tablets, packaged in a bottle containing 14 tablets – NDC 59088-003-81. KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN. Store at 20°-25°C (68°-77°F) [see USP Controlled Room Temperature]"],"effective_time":"20241011","adverse_reactions":["Adverse Reactions: Adverse reactions associated with the use of Bruising Tablets may include mild gastrointestinal discomfort, nausea, or allergic reactions such as skin rash. In rare cases, more serious reactions, such as prolonged bleeding or hypersensitivity reactions (e.g., difficulty breathing, swelling), may occur. If you experience any serious adverse effects, discontinue use and seek medical attention immediately."],"contraindications":["CONTRAINDICATIONS: Do not use if you have a known allergy to any of the ingredients in Bruselix™ Bruising Tablets , including Arnica Montana or pineapple (Bromelain). Avoid use if you have an allergy to citrus or bioflavonoid components."],"drug_interactions":["Drug Interactions: The use of anticoagulants, such as warfarin or aspirin, may increase the risk of bleeding when combined with Bromelain. High doses of zinc can interfere with the absorption of iron when taken alongside iron supplements. Additionally, citrus bioflavonoids have the potential to enhance the effects of blood pressure-lowering medications."],"indications_and_usage":["INDICATIONS AND USAGE: Bruselix™ Bruising Tablets are formulated to provide nutritional support during the body’s natural recovery process. They may be helpful for individuals experiencing bruising due to minor injuries, surgical procedures, or sensitive skin. The formula contains antioxidants, enzymes, and natural extracts that are traditionally used to support overall skin health and recovery."],"warnings_and_cautions":["WARNINGS AND PRECAUTIONS Arnica: May cause allergic reactions in sensitive individuals, especially if there is a history of ragweed allergies. Bromelain: May increase the risk of bleeding in individuals taking anticoagulants or antiplatelet medications. Discontinue use two weeks before surgery. Zinc and Vitamin C: Use cautiously in individuals with kidney disease or those prone to kidney stones. If you experience an allergic reaction or prolonged bleeding, discontinue use and seek medical attention immediately. For use on the order of a licensed healthcare practitioner. Call your doctor about side effects. To report side effects, call PureTek Corporation at 1-877-921-7873."],"dosage_and_administration":["DOSAGE AND ADMINISTRATION: Take one (1) Bruselix™ Bruising Tablets daily, or as directed by a licensed healthcare practitioner. Do not exceed recommended dose."],"spl_product_data_elements":["Bruselix Bruising Vitamin C, Zinc, Arnica Montana Extract, Bromelain, Diosmin, Rutin, Citrus Bioflavonoids, Hesperidin Methyl Chalcone ARNICA MONTANA FLOWER ARNICA MONTANA FLOWER MAGNESIUM STEARATE STEM BROMELAIN STEM BROMELAIN STEARIC ACID SODIUM ASCORBATE ASCORBIC ACID POLYETHYLENE GLYCOL 400 HESPERIDIN METHYLCHALCONE HESPERIDIN RUTIN RUTIN DIOSMIN DIOSMIN HESPERIDIN HESPERIDIN MICROCRYSTALLINE CELLULOSE 102 DIBASIC CALCIUM PHOSPHATE DIHYDRATE SILICON DIOXIDE HYPROMELLOSE, UNSPECIFIED ZINC PICOLINATE ZINC CATION CROSCARMELLOSE SODIUM yellow to brown speckled oblong caplet"],"package_label_principal_display_panel":["LABEL Manufactured by: PureTek Corporation Panorama City, CA 91402 For questions or information call toll-free: 877-921-7873 Label"]},"tags":[{"label":"diosmin","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Inhibitor of nuclear factor kappa-B kinase subunit beta","category":"target"},{"label":"IKBKB","category":"gene"},{"label":"KDM1A","category":"gene"},{"label":"C05CA03","category":"atc"},{"label":"Active","category":"status"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"llr":89.433,"date":"","count":14,"signal":"Blood lactic acid","source":"DrugCentral FAERS","actionTaken":"Reported 14 times (LLR=89)"},{"llr":70.045,"date":"","count":11,"signal":"Tubulointerstitial nephritis and uveitis syndrome","source":"DrugCentral FAERS","actionTaken":"Reported 11 times (LLR=70)"},{"llr":63.735,"date":"","count":19,"signal":"Erysipelas","source":"DrugCentral FAERS","actionTaken":"Reported 19 times (LLR=64)"},{"llr":42.394,"date":"","count":13,"signal":"Hypercapnia","source":"DrugCentral FAERS","actionTaken":"Reported 13 times (LLR=42)"},{"llr":37.219,"date":"","count":10,"signal":"Myoglobin blood increased","source":"DrugCentral FAERS","actionTaken":"Reported 10 times (LLR=37)"},{"llr":37.178,"date":"","count":18,"signal":"Ventricular tachycardia","source":"DrugCentral FAERS","actionTaken":"Reported 18 times (LLR=37)"},{"llr":30.881,"date":"","count":6,"signal":"Lentigo maligna","source":"DrugCentral FAERS","actionTaken":"Reported 6 times (LLR=31)"},{"llr":29.738,"date":"","count":20,"signal":"Delirium","source":"DrugCentral FAERS","actionTaken":"Reported 20 times (LLR=30)"}],"commonSideEffects":[{"effect":"Blood lactic acid","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Tubulointerstitial nephritis and uveitis syndrome","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Erysipelas","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Hypercapnia","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Myoglobin blood increased","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Ventricular tachycardia","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Lentigo maligna","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Delirium","drugRate":"","severity":"common","_validated":false,"_confidence":0.3}]},"trials":[],"aliases":[],"patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=DIOSMIN","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:45:00.938554+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:45:06.261106+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=DIOSMIN","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:45:06.561159+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:44:59.691206+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:44:59.691237+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL231884/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:45:07.267307+00:00"}},"allNames":"diosmil","offLabel":[],"synonyms":["diosmin","barosmin","diosmil","diosmine","flebosten","flebosmil"],"timeline":[],"brandName":"Diosmil","ecosystem":[],"mechanism":{"target":"Inhibitor of nuclear factor kappa-B kinase subunit beta, Lysine-specific histone demethylase 1A","targets":[{"gene":"IKBKB","source":"DrugCentral","target":"Inhibitor of nuclear factor kappa-B kinase subunit beta","protein":"Inhibitor of nuclear factor kappa-B kinase subunit beta"},{"gene":"KDM1A","source":"DrugCentral","target":"Lysine-specific histone demethylase 1A","protein":"Lysine-specific histone demethylase 1A"}],"modality":"Small Molecule","drugClass":"diosmin","explanation":"","oneSentence":"","technicalDetail":"Diosmil inhibits the activity of nuclear factor kappa-B kinase subunit beta (IKKβ), a key component of the NF-κB signaling pathway, which plays a central role in the regulation of inflammatory responses."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/3157","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=DIOSMIN","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=DIOSMIN","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T02:43:01.139408","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:45:10.558426+00:00","fieldsConflicting":9,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"crizotinib","drugSlug":"crizotinib","fdaApproval":"2011-08-26","patentExpiry":"Oct 8, 2029","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"fedratinib","drugSlug":"fedratinib","fdaApproval":"2019-08-16","patentExpiry":"Sep 24, 2039","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"fostamatinib","drugSlug":"fostamatinib","fdaApproval":"2018-04-17","patentExpiry":"Sep 4, 2031","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"midostaurin","drugSlug":"midostaurin","fdaApproval":"2017-04-28","patentExpiry":"Oct 9, 2028","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"ruxolitinib","drugSlug":"ruxolitinib","fdaApproval":"2011-11-16","patentExpiry":"Sep 4, 2040","patentStatus":"Patent protected","relationship":"same-target"}],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"genericName":"diosmin","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"crizotinib","brandName":"crizotinib","genericName":"crizotinib","approvalYear":"2011","relationship":"same-target"},{"drugId":"fedratinib","brandName":"fedratinib","genericName":"fedratinib","approvalYear":"2019","relationship":"same-target"},{"drugId":"fostamatinib","brandName":"fostamatinib","genericName":"fostamatinib","approvalYear":"2018","relationship":"same-target"},{"drugId":"midostaurin","brandName":"midostaurin","genericName":"midostaurin","approvalYear":"2017","relationship":"same-target"},{"drugId":"ruxolitinib","brandName":"ruxolitinib","genericName":"ruxolitinib","approvalYear":"2011","relationship":"same-target"}],"trialDetails":[{"nctId":"NCT07369635","phase":"PHASE3","title":"A Phase III Clinical Trial Evaluating the Efficacy and Safety of TriThien Duoc Capsules in Grade II Internal Haemorrhoids Patients With Bleeding Compared to Diosmin.","status":"COMPLETED","sponsor":"Hanoi Medical University","startDate":"2020-07-10","conditions":["Grade II Internal Hemorrhoids With Bleeding"],"enrollment":172,"completionDate":"2020-11-30"},{"nctId":"NCT06579482","phase":"PHASE4","title":"Clinical Trial of Aesculus Hippocastanum and Associations Versus Diosmina and Hesperidina in Chronic Venous Insuficiency","status":"COMPLETED","sponsor":"Fundação Educacional Serra dos Órgãos","startDate":"2024-11-06","conditions":["Chronic Venous Insufficiency"],"enrollment":120,"completionDate":"2025-06-11"},{"nctId":"NCT07300735","phase":"NA","title":"Comparing Diosmin-Hesperidin and Loratadine to Prevent Bone Pain From G-CSF in Patients With Blood Cancers","status":"RECRUITING","sponsor":"Alexandria University","startDate":"2025-03-01","conditions":["Hematologic Malignancy","Neutropenia","Bone Pain"],"enrollment":88,"completionDate":"2026-07"},{"nctId":"NCT07293767","phase":"NA","title":"Silymarin vs Hesperidin/Diosmin in Fibromyalgia","status":"RECRUITING","sponsor":"Ain Shams University","startDate":"2024-11-16","conditions":["Fibromyalgia (FM)"],"enrollment":90,"completionDate":"2026-12-31"},{"nctId":"NCT06256575","phase":"NA","title":"Study of Diosmin for the Treatment of Digital Ulcers in Systemic Sclerosis","status":"RECRUITING","sponsor":"Primus Pharmaceuticals","startDate":"2025-05-02","conditions":["Scleroderma, Systemic","Digital Ulcer"],"enrollment":45,"completionDate":"2027-08-15"},{"nctId":"NCT07185386","phase":"NA","title":"Effects of a Dietary Supplement Composed of Diosmin, Hesperidin, Bromelain, and Ruscus Aculeatus on the Quality of Life in Subjects With Lower Limb Disorders Possibly Prodromal to Chronic Venous Disease","status":"RECRUITING","sponsor":"Ekalab S.r.l.","startDate":"2025-05-28","conditions":["Prodromal to Chronic Venous Disease"],"enrollment":84,"completionDate":"2027-01-31"},{"nctId":"NCT06560294","phase":"NA","title":"Glue Embolization vs Conservative Treatment for Pelvic Congestion Syndrome","status":"RECRUITING","sponsor":"Tanta University","startDate":"2024-08-17","conditions":["Glue Embolization","Pelvic Congestion Syndrome"],"enrollment":40,"completionDate":"2025-10-01"},{"nctId":"NCT06367166","phase":"NA","title":"Effects of Bioflavanoids on Vascular Wall Remodeling in Patients With Varicose Veins","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ryazan State Medical University","startDate":"2023-04-01","conditions":["Varicose Veins of Lower Limb","Varix","Vascular Diseases","Leg Edema"],"enrollment":100,"completionDate":"2026-05-01"},{"nctId":"NCT06753448","phase":"","title":"Efficacy of Diosmin and Hesperidin on Early Rehabilitation After Total Knee Arthroplasty","status":"COMPLETED","sponsor":"Ankara Etlik City Hospital","startDate":"2024-10-08","conditions":["Total Knee Arthroplasty","Venous Insufficiency of Leg"],"enrollment":190,"completionDate":"2025-06-10"},{"nctId":"NCT06184438","phase":"PHASE4","title":"Randomized Control Trial of Micronized Purified Flavonoid Fraction for Post Operative Treatment in Anal Fistula Surgery","status":"COMPLETED","sponsor":"Taipei Medical University Shuang Ho Hospital","startDate":"2023-12-13","conditions":["Anal Fistula"],"enrollment":106,"completionDate":"2025-03-31"},{"nctId":"NCT05756179","phase":"PHASE3","title":"Effect of Diosmin and Hesperidin in Treatment of Patients With Rheumatoid Arthritis","status":"RECRUITING","sponsor":"Alexandria University","startDate":"2023-07-18","conditions":["Rheumatoid Arthritis"],"enrollment":80,"completionDate":"2026-09"},{"nctId":"NCT06352099","phase":"NA","title":"Dietary Supplementation and Cognitive Functions in the Elderly","status":"COMPLETED","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2024-05-02","conditions":["Cognitive Impairment","Old Age; Debility"],"enrollment":36,"completionDate":"2025-02-17"},{"nctId":"NCT06811220","phase":"PHASE3","title":"The Effect of Oral Administration of Hesperidin and Diosmin in Reducing Paclitaxel-induced Peripheral Neuropathy in Breast Cancer Patients","status":"NOT_YET_RECRUITING","sponsor":"Alexandria University","startDate":"2025-01-27","conditions":["Breast Cancer"],"enrollment":140,"completionDate":"2027-12-31"},{"nctId":"NCT06352658","phase":"NA","title":"Efficacy of Different Treatments for Obstructive Sleep Apnea","status":"COMPLETED","sponsor":"Nourhan M.Aly","startDate":"2023-02-01","conditions":["Apnea"],"enrollment":45,"completionDate":"2024-01-10"},{"nctId":"NCT06333691","phase":"NA","title":"Comparative Study Between Calcium Gluconate With Diosmin, Cabergoline and Cabergoline With Diosmin","status":"COMPLETED","sponsor":"Minia University","startDate":"2022-10-01","conditions":["Ovarian Hyperstimulation Syndrome"],"enrollment":180,"completionDate":"2024-02-15"},{"nctId":"NCT06584799","phase":"PHASE3","title":"Venoactive Drug Treatment of Pelvic Venous Disorders","status":"RECRUITING","sponsor":"Pirogov Russian National Research Medical University","startDate":"2024-12","conditions":["Pelvic Venous Disorders"],"enrollment":150,"completionDate":"2025-02"},{"nctId":"NCT05616962","phase":"NA","title":"Vasculera in Participants With Lipedema","status":"COMPLETED","sponsor":"Primus Pharmaceuticals","startDate":"2019-05-26","conditions":["Lipedema"],"enrollment":34,"completionDate":"2019-09-23"},{"nctId":"NCT05736224","phase":"PHASE1","title":"Assessing a Natural Product Plus Bioadhesive Nanoparticle (BNP) Sunscreen","status":"COMPLETED","sponsor":"Yale University","startDate":"2023-05-15","conditions":["Skin Cancer"],"enrollment":30,"completionDate":"2023-09-01"},{"nctId":"NCT06546111","phase":"PHASE1,PHASE2","title":"Clinical Study to Evaluate the Possible Efficacy and Safety of Diosmin and Hesperidin Combined Therapy in Patients With Helicobacter Pylori Infection","status":"RECRUITING","sponsor":"Sadat City University","startDate":"2024-10-01","conditions":["Helicobacter Pylori Infection"],"enrollment":46,"completionDate":"2026-10-01"},{"nctId":"NCT06318988","phase":"","title":"Outcomes of Different Treatment Options in Chronic Venous Disease","status":"NOT_YET_RECRUITING","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2024-07-01","conditions":["Chronic Venous Disease"],"enrollment":2000,"completionDate":"2027-05-01"},{"nctId":"NCT02361437","phase":"NA","title":"Safety and Efficacy of Vasculera® in the Healing of Diabetic Skin Ulcers","status":"WITHDRAWN","sponsor":"Primus Pharmaceuticals","startDate":"2015-02","conditions":["Diabetic Ulcers"],"enrollment":0,"completionDate":"2015-10"},{"nctId":"NCT06125002","phase":"PHASE1","title":"Diosmin for Treatment of Delayed-onset Muscle Soreness (DOMS)","status":"UNKNOWN","sponsor":"Sergio Marques Borghi","startDate":"2024-01","conditions":["Myalgia"],"enrollment":20,"completionDate":"2024-05"},{"nctId":"NCT06083935","phase":"PHASE4","title":"Evaluation of the Effects of Diosmin/Hespiridin Combination on the Clinical Outcomes in Patients With Polycystic Ovary Syndrome","status":"UNKNOWN","sponsor":"Ain Shams University","startDate":"2023-11-01","conditions":["Poly Cystic Ovary Syndrome"],"enrollment":120,"completionDate":"2024-12-01"},{"nctId":"NCT05942547","phase":"PHASE3","title":"the Efficacy and Safety of Diosmin on Non-diabetic Patients With Non-alcoholic Steatohepatitis.","status":"UNKNOWN","sponsor":"Tanta University","startDate":"2023-07-10","conditions":["Non Alcoholic Steatohepatitis"],"enrollment":48,"completionDate":"2025-06-10"},{"nctId":"NCT05626166","phase":"PHASE3","title":"the Efficacy and Safety of Diosmin in Patients With Ulcerative Colitis","status":"UNKNOWN","sponsor":"Tanta University","startDate":"2022-12-15","conditions":["Ulcerative Colitis"],"enrollment":60,"completionDate":"2024-11"},{"nctId":"NCT05750563","phase":"NA","title":"Randomised, Double-blind, Placebo-controlled to Assess the Efficacy and Safety of the Food Supplement Microsmin® Plus","status":"UNKNOWN","sponsor":"Giellepi S.p.A","startDate":"2023-02-28","conditions":["Haemorrhoids"],"enrollment":80,"completionDate":"2023-12-30"},{"nctId":"NCT05670457","phase":"PHASE3","title":"Diosmin as Adjuvant Therapy in Treatment of Non-bleeding Peptic Ulcer","status":"UNKNOWN","sponsor":"Tanta University","startDate":"2022-06-30","conditions":["Non-bleeding Peptic Ulcer"],"enrollment":44,"completionDate":"2025-06"},{"nctId":"NCT04360889","phase":"PHASE4","title":"Lipid Peroxidation and Options Antioxidant Therapy for Secondary Lymphedema of the Lower Extremities","status":"COMPLETED","sponsor":"Ryazan State Medical University","startDate":"2019-09-01","conditions":["Lower Extremity Lymphedema"],"enrollment":120,"completionDate":"2022-08-03"},{"nctId":"NCT02158000","phase":"NA","title":"Aspiration of Excessive Endometrial Fluid at the Day of Ovum Retrieval Plus Diosmin in (ICSI) Cycles","status":"COMPLETED","sponsor":"Benha University","startDate":"2014-06","conditions":["Infertility"],"enrollment":200,"completionDate":"2021-11"},{"nctId":"NCT04687852","phase":"NA","title":"Comparison of the Efficacy of Pharmacology and Non-pharmacological Treatment in Women With Primary Dysmenorrhea.","status":"COMPLETED","sponsor":"Istanbul Medipol University Hospital","startDate":"2021-07-09","conditions":["Pelvic Floor","Exercise","Telerehabilitation","Acupressure","Dysmenorrhea Primary","Drug Effect"],"enrollment":85,"completionDate":"2021-12-10"},{"nctId":"NCT04933591","phase":"NA","title":"Impact of Treatment With VENARUS® on the Level of Monocyte Chemoattractant Protein 1 in Varicose Veins Blood","status":"COMPLETED","sponsor":"Pirogov Russian National Research Medical University","startDate":"2020-09-01","conditions":["Varicose Veins"],"enrollment":30,"completionDate":"2021-09-28"},{"nctId":"NCT04290351","phase":"","title":"The Effect of Rubber Band Ligation in Bleeding Internal Hemorrhoids.","status":"COMPLETED","sponsor":"Konya Meram State Hospital","startDate":"2020-11-01","conditions":["Hemorrhoids, Internal"],"enrollment":69,"completionDate":"2021-12-20"},{"nctId":"NCT05243706","phase":"PHASE3","title":"Evaluation of The Effect of Loratadine Versus Diosmin/Hesperidin Combination on Vinca Alkaloids Induced Neuropathy","status":"UNKNOWN","sponsor":"Ain Shams University","startDate":"2022-03-01","conditions":["Vinca Alkaloid Adverse Reaction"],"enrollment":90,"completionDate":"2023-12-30"},{"nctId":"NCT05243238","phase":"NA","title":"Hesperidin and Diosmin Effect on Metabolic Syndrome","status":"COMPLETED","sponsor":"Beni-Suef University","startDate":"2020-03-01","conditions":["Metabolic Syndrome and Diabetic Neuropathy"],"enrollment":129,"completionDate":"2021-11-12"},{"nctId":"NCT05158192","phase":"PHASE1","title":"Bioavailability of Diosmin/Hesperidin (90/10) 500 mg Tablets With Regards to Reference Product","status":"COMPLETED","sponsor":"Laboratorios Andromaco S.A.","startDate":"2021-11-04","conditions":["Bioequivalence"],"enrollment":12,"completionDate":"2021-12-14"},{"nctId":"NCT05113420","phase":"","title":"The Efficacy and Safety of Different Phlebotonic Drugs in Children With Venous Malformations","status":"UNKNOWN","sponsor":"Center for Vascular Pathology, Moscow","startDate":"2019-09-17","conditions":["Drug Effect","Children, Only","Vascular Malformations","Surgery"],"enrollment":1000,"completionDate":"2022-09-17"},{"nctId":"NCT03413618","phase":"PHASE4","title":"Rivaroxaban With Diosmin in Long-term Treatment of Deep Vein Thrombosis","status":"COMPLETED","sponsor":"Pirogov Russian National Research Medical University","startDate":"2017-12-20","conditions":["Deep Vein Thrombosis","Postthrombotic Syndrome"],"enrollment":90,"completionDate":"2019-07-31"},{"nctId":"NCT04512443","phase":"","title":"Clinical Efficacy of Conservative Treatment in Female Patients With Plevic Congestion Syndrome","status":"COMPLETED","sponsor":"Interregional Clinical Diagnostic Center, Russia","startDate":"2019-12-28","conditions":["Pelvic Congestion Syndrome"],"enrollment":83,"completionDate":"2020-03-28"},{"nctId":"NCT04452799","phase":"EARLY_PHASE1","title":"Hesperidin and Diosmin for Treatment of COVID-19","status":"UNKNOWN","sponsor":"Tanta University","startDate":"2020-07-01","conditions":["Coronavirus Infection"],"enrollment":100,"completionDate":"2020-10-30"},{"nctId":"NCT04101201","phase":"NA","title":"Clinical Trial to Assess the Efficacy of µSmin® Plus","status":"COMPLETED","sponsor":"Giellepi S.p.A","startDate":"2019-11-15","conditions":["Chronic Venous Disease"],"enrollment":73,"completionDate":"2020-04-24"},{"nctId":"NCT04358497","phase":"PHASE4","title":"Endovascular Versus Medical Treatment for the Pelvic Congestion Syndrome","status":"UNKNOWN","sponsor":"Hospital de Clínicas Dr. Manuel Quintela","startDate":"2020-10-01","conditions":["Pelvic Congestive Syndrome","Pelvic Varices","Venous Disease"],"enrollment":120,"completionDate":"2022-10-01"},{"nctId":"NCT01654016","phase":"PHASE4","title":"Study of Antiinflammatory Effects of Detralex (Daflon)","status":"COMPLETED","sponsor":"University Hospital Dubrava","startDate":"2012-08","conditions":["Chronic Venous Insufficiency"],"enrollment":84,"completionDate":"2019-09"},{"nctId":"NCT02782455","phase":"PHASE4","title":"Calcium Dobesilate vs Flavonoids for the Treatment of Early Hemorrhoidal Disease","status":"COMPLETED","sponsor":"Services Hospital, Lahore","startDate":"2016-12-01","conditions":["Hemorrhoids"],"enrollment":100,"completionDate":"2018-11-30"},{"nctId":"NCT03471910","phase":"PHASE4","title":"Clinical Non-inferiority Study Between Diosmin 600mg & Diosmin + Hesperidin in Symptomatic Chronic Venous Insufficiency","status":"COMPLETED","sponsor":"Fundação Educacional Serra dos Órgãos","startDate":"2017-06-20","conditions":["Venous Insufficiency"],"enrollment":120,"completionDate":"2018-04-30"},{"nctId":"NCT02927483","phase":"PHASE3","title":"Study to Assess the Efficacy and Safety of Endolex Forte VErsus Diosmin and Hesperidin in Reducing VeNous Insufficiency","status":"UNKNOWN","sponsor":"SunWave Pharma","startDate":"2016-11","conditions":["Chronic Venous Insufficiency"],"enrollment":120,"completionDate":"2017-06"},{"nctId":"NCT02134249","phase":"PHASE2,PHASE3","title":"Diosmin Versus Cabergoline for Prevention of Ovarian Hyperstimulation Syndrome","status":"COMPLETED","sponsor":"Benha University","startDate":"2014-04","conditions":["Infertility"],"enrollment":200,"completionDate":"2015-10"},{"nctId":"NCT02616731","phase":"PHASE1,PHASE2","title":"Oral Tranexamic Acid Versus Diosmin for Treatment of Menorrhagia in Women Using Copper IUD","status":"UNKNOWN","sponsor":"Ain Shams University","startDate":"2015-09","conditions":["Menorrhagia"],"enrollment":100,"completionDate":"2016-03"},{"nctId":"NCT01532882","phase":"PHASE3","title":"Efficacy and Safety of Diosmin 600mg Versus Placebo on Painful Symptomatology in Patients With Chronic Venous Disease of Lower Limbs","status":"COMPLETED","sponsor":"Laboratoire Innotech International","startDate":"2012-01","conditions":["Chronic Venous Disease of Lower Limbs"],"enrollment":378,"completionDate":"2013-04"},{"nctId":"NCT01477281","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Tolerability of Venaflon Use in Reducing the Symptoms Caused by Chronic Venous Insufficiency When Compared With Daflon","status":"UNKNOWN","sponsor":"Laboratório Teuto Brasileiro S/A","startDate":"2012-02","conditions":["Chronic Venous Insufficiency","Disease"],"enrollment":82,"completionDate":"2012-08"},{"nctId":"NCT01321619","phase":"PHASE3","title":"Efficacy and Tolerability of the Use of Varicell Compared With Daflon","status":"UNKNOWN","sponsor":"Vidfarma Indústria de Medicamentos Ltda.","startDate":"2011-07","conditions":["Chronic Venous Insufficiency","Hemorrhoids"],"enrollment":102,"completionDate":"2011-12"},{"nctId":"NCT01110512","phase":"PHASE3","title":"Comparative Efficacy of Two Preparations of the Association Diosmin (450 mg) + Hesperidin (50 mg) in the Treatment of Chronic Venous Insufficiency (CVI)","status":"UNKNOWN","sponsor":"Azidus Brasil","startDate":"2010-10","conditions":["Venous Insufficiency"],"enrollment":140,"completionDate":"2011-03"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Oral"},"crossReferences":{"NUI":"N0000167025","NDDF":"005803","UNII":"7QM776WJ5N","CHEBI":"CHEBI:4631","VANDF":"4036523","INN_ID":"4370","RXNORM":"3489","UMLSCUI":"C0012498","chemblId":"CHEMBL231884","ChEMBL_ID":"CHEMBL231884","KEGG_DRUG":"D07858","DRUGBANK_ID":"DB08995","PUBCHEM_CID":"5281613","SNOMEDCT_US":"126142004","MESH_DESCRIPTOR_UI":"D004145"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":733,"therapeuticAreas":["Pain"],"atcClassification":{"source":"DrugCentral","atcCode":"C05CA03","allCodes":["C05CA03","C05CA53"]},"biosimilarFilings":[],"recentPublications":[{"date":"2026 Mar 20","pmid":"41903244","title":"Assessment of the inaccuracy associated with the quantification of phenolic compounds using UHPLC-DAD and HPLC-MS/MS.","journal":"Journal of chromatography. A"},{"date":"2026 Mar 24","pmid":"41876507","title":"Stage-specific nutritional blueprints of date fruit revealed by integrated LC-MS metabolomics and ICP-OES profiling.","journal":"NPJ science of food"},{"date":"2026 Mar 18","pmid":"41862140","title":"Smart Lipid-Based Nanocarrier System for the Topical Delivery of Ocular Therapeutics Bio-Interfacing, Physicochemical Diversity, and Routing Barriers.","journal":"European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences"},{"date":"2026 Feb","pmid":"41830372","title":"The Flavonoids Hesperidin and Diosmin: Adjuvant Therapy for Obesity.","journal":"JPMA. The Journal of the Pakistan Medical Association"},{"date":"2026","pmid":"41767423","title":"Effectiveness of Conservative Treatment on Chronic Venous Disease Symptoms and Quality of Life in Patients with Type 2 Diabetes: Results from a Subanalysis of the VEIN STEP Observational Study.","journal":"Vascular health and risk management"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"withdrawn","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:45:10.558426+00:00","fieldsConflicting":9,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":false,"safety":true,"trials":true,"score":2}}